Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral vector-based gene therapy ? ET3 ? for hemophilia A at the Annual Meeting of the American ...
ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stageEarly clinical data are expected in second half of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback